Ranbaxy Talks Up Monetization Of First To Files Like Lipitor, Diovan, Actos if FDA Issues Stay Foggy; Are Big Launches Imperilled?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - With no clarity emerging whatsoever on how Ranbaxy Laboratories Ltd. will resolve its five-year long dispute with U.S. FDA - which has led to a blanket ban on drugs manufactured at one of Ranbaxy's largest India-based sites - analysts now speculate that the company will most likely "explore monetizing" its key first-to-file opportunities in the U.S. like Lipitor (atorvastatin), Diovan (valsartan), Nexium (esomeprazole) and Actos (pioglitazone)